Page 1 | Search Results | Blood Advances | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-20 of 20857

1

Sort by

Sort Order Select

Journal Articles

Digital cognitive behavioral therapy vs education for pain in adults with sickle cell disease

Blood Adv (2024) 8 (24): 6257–6266.

https://doi.org/10.1182/bloodadvances.2024013861

Published: 2024

Journal Articles

Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy

Geoffrey L. Uy, Vinod Pullarkat, Praneeth Baratam, Robert K. Stuart, Roland B. Walter, Eric S. Winer, Qi Wang, Stefan Faderl, Divya Chakravarthy, Diane Menno, Ronald S. Cheung, Tara L. Lin

Blood Adv (2024) 8 (24): 6248–6256.

https://doi.org/10.1182/bloodadvances.2024013687

Published: 2024

Includes: Supplemental data

Images

CONSORT flow diagram of CaRISMA trial. Participant flow through screening,...

CONSORT flow diagram of CaRISMA trial. Participant flow through screening,...

in Digital cognitive behavioral therapy vs education for pain in adults with sickle cell disease > Blood Advances

Published: 2024

Figure 1. CONSORT flow diagram of CaRISMA trial. Participant flow through screening, randomization, allocation, and follow-up. Numbers of participants screened and randomly assigned to CBT or Education arms, completed assessments, missed follow-ups, and withdrawals at 3 and 6 months are shown. L... More about this image found in CONSORT flow diagram of CaRISMA trial. Participant flow through screening,...

Journal Articles

HIV infection is associated with compromised tumor microenvironment adaptive immune reactivity in Hodgkin lymphoma

Amanda Chantziou, Cloe Brenna, Kalliopi Ioannidou, Oliver Y. Chen, Penelope Korkolopoulou, Anastasia Antoniadou, Mina Psichogiou, Maria Papaioannou, Panagiotis Tsirigotis, Periklis G. Foukas, Laurence de Leval, Constantinos Petrovas

Blood Adv (2024) 8 (24): 6215–6231.

https://doi.org/10.1182/bloodadvances.2023012116

Published: 2024

Includes: Supplemental data

Journal Articles

Evolving consolidation patterns and outcomes for a large cohort of patients with primary CNS lymphoma

Kathryn R. Tringale, Michael Scordo, Joachim Yahalom, Charlie White, Zhigang Zhang, Javin Schefflein, Gustav Cederquist, Lauren R. Schaff, Lisa DeAngelis, Brandon S. Imber, Christian Grommes

Blood Adv (2024) 8 (24): 6195–6206.

https://doi.org/10.1182/bloodadvances.2024013780

Published: 2024

Includes: Supplemental data

Journal Articles

Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration

Nektarios Kostopoulos, Francesca Costabile, Elisavet Krimitza, Silvia Beghi, Denisa Goia, Renzo Perales-Linares, George Thyfronitis, Michael J. LaRiviere, Elise A. Chong, Stephen J. Schuster, Amit Maity, Constantinos Koumenis, John P. Plastaras, Andrea Facciabene

Blood Adv (2024) 8 (24): 6308–6320.

https://doi.org/10.1182/bloodadvances.2024012599

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy and safety of TPO receptor agonists in treatment of ITP associated with predominantly antibody deficiencies

Margaux Soulard, Lionel Galicier, Nizar Mahlaoui, Claire Fieschi, Samuel Deshayes, Delphine Gobert, Clément Gourguechon, Hélène Henique, Sebastien Humbert, Carole Lacout, Ronan Le Calloch, Marc Michel, Marie-lea Piel-julian, Jean François Viallard, Alain Lescoat, Bertrand Godeau, Antoinette Perlat

Blood Adv (2024) 8 (24): 6171–6182.

https://doi.org/10.1182/bloodadvances.2024014370

Published: 2024

Journal Articles

Identification of factors predicting low-risk febrile neutropenia admissions in adults with acute myeloid leukemia

Khushboo V. Pal, Megan Othus, Zahra Ali, Katherine Russell, Carole Shaw, Mary-Elizabeth M. Percival, Paul C. Hendrie, Jacob S. Appelbaum, Roland B. Walter, Anna B. Halpern

Blood Adv (2024) 8 (24): 6161–6170.

https://doi.org/10.1182/bloodadvances.2024014291

Published: 2024

Includes: Supplemental data

Journal Articles

PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas

Blood Adv (2024) 8 (24): 6268–6281.

https://doi.org/10.1182/bloodadvances.2023012291

Published: 2024

Includes: Supplemental data

Journal Articles

Guideline concordance of aspirin use for primary prevention in adult outpatients

Naina Chipalkatti, Geoffrey D. Barnes, Linda Bashaw, Adam Davie, Jennifer J. Griggs, Molly Harrod, Jacob E. Kurlander, Christine Medaugh, Rebeca Packard, Corey Powell, Suman Sood, Elizabeth Spranger, Sarah E. Vordenberg, Jordan K. Schaefer

Blood Adv (2024) 8 (24): 6207–6214.

https://doi.org/10.1182/bloodadvances.2024014220

Published: 2024

Includes: Supplemental data

Journal Articles

Sustained remission at long term follow-up in adolescents and young adults with chronic primary immune thrombocytopenia

Alexandra Schifferli, Gautier Le Gavrian, Nathalie Aladjidi, Guillaume Moulis, Bertrand Godeau, Thierry Leblanc, Sébastien Héritier, Helder Fernandes, Thomas Kühne

Blood Adv (2024) 8 (24): 6183–6194.

https://doi.org/10.1182/bloodadvances.2024014381

Published: 2024

Includes: Supplemental data

Journal Articles

American Society of Hematology: building a comprehensive minority recruitment and retention professional program

Margo R. Rollins, Rahma M. Warsame, Melody Smith, Arturo Molina, Rayne H. Rouce, Belinda R. Avalos, Cage S. Johnson, Jose A. Lopez, Alexis A. Thompson, Lisa Fanning, Patricia Frustace, Keelin Roche, Nathalie van Havre, Devon Mack, Christopher R. Flowers, Deirdra R. Terrell

Blood Adv (2024) 8 (24): 6237–6247.

https://doi.org/10.1182/bloodadvances.2024013519

Published: 2024

Journal Articles

Cardiovascular toxicities associated with novel cellular immune therapies

Malak Munir, Ahmed Sayed, Daniel Addison, Narendranath Epperla

Blood Adv (2024) 8 (24): 6282–6296.

https://doi.org/10.1182/bloodadvances.2024013849

Published: 2024

Journal Articles

Impact of thrombocytopenia on bleeding and thrombotic outcomes in adults with cancer-associated splanchnic vein thrombosis

Michael Andersen, Jr., Maria J. Fernandez Turizo, Laura E. Dodge, Charles Hsu, Kevin Barnum, Jonathan Berry, Jeffrey I. Zwicker, Rushad Patell

Blood Adv (2024) 8 (24): 6151–6160.

https://doi.org/10.1182/bloodadvances.2024014249

Published: 2024

Includes: Supplemental data

Journal Articles

Incidence of preexisting B-cell aplasia in B-ALL: implications for post–CAR T-cell monitoring

Isha Sahai, Paul Borgman, Bonnie Yates, Sergio Rosenzweig, Shakuntala Rampertaap, Alexander W. Rankin, Nirali N. Shah

Blood Adv (2024) 8 (24): 6329–6333.

https://doi.org/10.1182/bloodadvances.2024014641

Published: 2024

Journal Articles

Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes

Blood Adv (2024) 8 (24): 6297–6307.

https://doi.org/10.1182/bloodadvances.2024013327

Published: 2024

Includes: Supplemental data

Journal Articles

Retreatment of multiple myeloma with previously refractory drugs

Blood Adv (2024) 8 (24): 6321–6328.

https://doi.org/10.1182/bloodadvances.2024014723

Published: 2024

Includes: Supplemental data

Journal Articles

Time to revisit reduced-dose radiotherapy for PCNSL?

Maciej Tatarczuch

Blood Adv (2024) 8 (24): 6234–6236.

https://doi.org/10.1182/bloodadvances.2024014588

Published: 2024

Journal Articles

Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Adv. 2023;7(23):7153-7160.

Blood Adv (2024) 8 (24): 6232–6233.

https://doi.org/10.1182/bloodadvances.2024014741

Published: 2024

Journal Articles

Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.

Blood Adv (2024) 8 (24): 6267.

https://doi.org/10.1182/bloodadvances.2024015206

Published: 2024

1